nature portfolio

Corresponding author(s):	Ursula S. Hofstoetter
Last updated by author(s):	Apr 24, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

~		100		
5	ta	ŤΙ	ST	ICS

n/a	Confirmed
	$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🗴 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	🗶 A description of all covariates tested
	🗴 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	🗷 For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	$oxed{x}$ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above

Software and code

Policy information about availability of computer code

Data collection

Electromyographic signals were amplified (Grass Instruments, Quincy, MA, USA) with a gain of 2000, filtered to a bandwidth of 30–700 Hz, and digitized at 2002 samples per second and channel using a Codas analog-to-digital converter system (Dataq Instruments, Akron, OH, USA).

Data analysis

IBM SPSS Statistics 27.0 for Windows (IBM Corporation, Armonk, NY, USA)
Matlab 2017b (The MathWorks, Inc., Natick, MA, USA) Grass Instruments, Quincy, MA, USA

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files. Source data are provided with this paper.

Policy informatio	n about <u>studies</u>	involving human research participants and Sex and Gender in Research.			
Reporting on sex and gender		single male individual			
Population characteristics		spinal cord injury, hip pathology, rare form of spinal myoclonus, spinal cord stimulator, age: 23.4 years			
Recruitment		retrospective analysis of clinical data			
Ethics oversight		The study participant gave written informed consent for all interventions and procedures reported in the manuscript as well as for data processing and publication. Retrospective data analysis was approved by the Ethics Committee of the City of Vienna, Austria.			
Note that full infor	mation on the app	proval of the study protocol must also be provided in the manuscript.			
Field-sn	ecific r	eporting			
•		: is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Please select the					
_		Pohavioural & cocial sciences			
x Life sciences	of the document wit	Behavioural & social sciences			
x Life sciences	of the document wit	Behavioural & social sciences			
Life sciences		th all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life sciences For a reference copy of					
Life sciences	nces st	th all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life sciences	nces st disclose on thes	th all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life sciences Cor a reference copy of the science sci	nces st disclose on thes	th all sections, see nature.com/documents/nr-reporting-summary-flat.pdf EUCLY design e points even when the disclosure is negative. cal method was used to predetermine sample size. Data were selected because the participant presented with a very rare form of the sample of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size.			
Life sciences For a reference copy of Life Scie All studies must of Sample size	disclose on thes 1. No statistic spinal myoclo limbs, and ha	th all sections, see nature.com/documents/nr-reporting-summary-flat.pdf EUCLY design e points even when the disclosure is negative. cal method was used to predetermine sample size. Data were selected because the participant presented with a very rare form of the sample of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size. Data were selected because the participant presented with a very rare form of the sample size.			
Life sciences For a reference copy of Life scie All studies must of Sample size Data exclusions	disclose on thes 1. No statistic spinal myoclo limbs, and ha No data were	th all sections, see nature.com/documents/nr-reporting-summary-flat.pdf EUCLY design e points even when the disclosure is negative. cal method was used to predetermine sample size. Data were selected because the participant presented with a very rare form of the sample of the sample of the sample size. Data were selected because the participant presented with a very rare form of the sample of the sampl			
Life sciences For a reference copy of Life scie All studies must of Sample size Data exclusions Replication	1. No statistic spinal myoclo limbs, and ha No data were Nine neurolog	th all sections, see nature.com/documents/nr-reporting-summary-flat.pdf Eudy design e points even when the disclosure is negative. tal method was used to predetermine sample size. Data were selected because the participant presented with a very rare form of the sample of the sample of the second of the sample of the sam			
Life sciences For a reference copy of Life scie All studies must of Sample size Data exclusions Replication Randomization	1. No statistic spinal myoclo limbs, and ha No data were Nine neurolog	e points even when the disclosure is negative. Ital method was used to predetermine sample size. Data were selected because the participant presented with a very rare form of the control of the production of t			
Life sciences For a reference copy of Life Scie All studies must of Sample size Data exclusions Replication Randomization Blinding	Inces statistics spinal myoclo limbs, and han No data were Nine neurolog The clinical ex	e points even when the disclosure is negative. Ital method was used to predetermine sample size. Data were selected because the participant presented with a very rare form of the control of the production of t			

iterials & experimental systems	Methods	
Involved in the study	n/a Involved in the study	
Antibodies	ChIP-seq	
Eukaryotic cell lines	Flow cytometry	
Palaeontology and archaeology	MRI-based neuroimaging	
Animals and other organisms		
✗ Clinical data		
Dual use research of concern		
	Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data	

Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJEguidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration This study was not conceived as a preospective clinical study and therefore was not registered.

Study protocol Not a clinical study.

Data collection Data were collected at the Neurological Center, Otto-Wagner-Hospital, Vienna, Austria, over a 3-month time period following

standard clinical routine.

Outcomes Rhythm and multi-muscle activation patterns of specific events within electromyographically recorded data